### Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

<table>
<thead>
<tr>
<th>Last Name</th>
<th>Role in Activity</th>
<th>Commercial Interest</th>
<th>Nature of Relevant Financial Relationship</th>
</tr>
</thead>
</table>
| Algazi    | Speaker         | • Acerta Pharma, AstraZeneca, Bristol-Myers Squibb, Dynamic Pharma Group, Genentech, Incyte, Medimmune, Merck, Oncosec Medical, Tessa Therapeutics, Valitor, Arma Pharma | • Research Support  
  • Principal Investigator  
  • Advisory Board |
| Ali       | Speaker         | • Amgen               | • Honorarium  
  • Speakers Bureau |
| Daniels   | Speaker         | • Array BioPharma, Regeneron, Sanofi | • Consultant  
  • Honorarium |
| Hecht     | Speaker         | • Audro Biotech, Bristol-Myers Squibb, Halozyme, Inc, Ipsen, Rafael Pharmaceuticals, Inc., Roche, AbbVie Inc., Advaxis, Amgen, Forty Seven Inc., Halozyme, Inc., Merck, Novartis” | • Honorarium  
  • Advisory Board  
  • Research Support |
| Kosty     | Speaker         | • Amgen, EMD Serono Inc., Genentech, Merck & Co., Bioccept Inc. | • Research Support  
  • Consultant  
  • Grants  
  • Consulting Fees |
| Mahindra  | Speaker         | • Genentech, Gilead/Kite, Oncopeptides, Amgen, Janssen, Sanofi | • Advisory Board  
  • Speakers Bureau  
  • Honorarium  
  • Honorarium |
| Mortimer  | Speaker         | • Karyopharm Therapeutics Pfizer, Puma Biotechnology Inc., Novartis Pharmaceuticals | • Honorarium  
  • Consultant |
| Natale    | Speaker         | • Amgen, AstraZeneca, Bristol-Myers Squibb, Jansen | • Research Support  
  • Principle Investigator |
| Quinn     | Speaker         | • Amgen, Astellas Pharma, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Dendreon, Eisai, EMD Serono, Genentech/Roche, Janssen Oncology, Merck Sharp & Dohme, Merck Serono, Peloton Therapeutics, Pfizer, Piramal Life Science, Sanofi, Genentech/Roche, GlaxoSmithKline, Millennium, Sanofi, AstraZeneca, Dendreon, EMD Serono, Exelixis, Peloton Therapeutics, Sanofi, Astellas Pharma, AstraZeneca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Exelixis, Genentech/Roche, Merck Sharp & Dohme, Pfizer | • Honorarium  
  • Advisory Board  
  • Research Support  
  • Expert Testimony  
  • Consulting Fees  
  • Consultant |
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Financial Relationships</th>
<th>ACCME Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saven</td>
<td>Course Director</td>
<td>• AbbVie Inc., Amgen, AstraZeneca, Celgene, Incyte, Pharmacyclics, Seattle Genetics, Takeda Pharmaceuticals</td>
<td>• Speaker &amp; Advisory Board • Honorarium</td>
</tr>
<tr>
<td>Saven</td>
<td>Course Director</td>
<td>• AbbVie Inc., Amgen, AstraZeneca, Celgene, Incyte, Pharmacyclics, Seattle Genetics, Takeda Pharmaceuticals</td>
<td>• Speaker &amp; Advisory Board • Honorarium</td>
</tr>
<tr>
<td>Sigal</td>
<td>Speaker</td>
<td>• Celgene • Genentech, Molecular Response</td>
<td>• Honorarium • Speakers Bureau • Advisory Board</td>
</tr>
<tr>
<td>Srinivas</td>
<td>Speaker</td>
<td>• Bayer, Esai, Jannsen</td>
<td>• Advisory Board • Honorarium</td>
</tr>
<tr>
<td>CME Committee</td>
<td>Review of all CME content</td>
<td>• None</td>
<td>• N/A • N/A</td>
</tr>
<tr>
<td>Scripps Conference Services &amp; CME</td>
<td>Plan, manage, implement, and reconcile activity</td>
<td>• None</td>
<td>• N/A • N/A</td>
</tr>
</tbody>
</table>

**Glossary of Terms**

**Commercial Interest**

The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit [www.accme.org](http://www.accme.org).

**Financial Relationships**

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

**Relevant Financial Relationships**

ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “‘relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

**Conflict of Interest**

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or service of a commercial interest with which he/she has a financial relationship.